Multiplicity of infection

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Retrieved on: 
Wednesday, August 24, 2022
Mortality, Security (finance), Decision-making, Human, CEO, Safety, Hospital, Therapy, Disease, Multiplicity of infection, Risk, Time-invariant system, U.S. Securities and Exchange Commission, Animal, GLOBE, Patient, Nasdaq, FDA, Immunotherapy, Immune system, Ironi Nes Ziona B.C., Sepsis, Marketing, Annual report, Private Securities Litigation Reform Act, Convenience food, Medical imaging, Pharmaceutical industry, Medical device, SOFA

Enlivex expects that broad acceptance of the proposed amendments will shorten the timeline for potential regulatory approval of frozen Allocetra formulation in sepsis and its associated commercial launch.

Key Points: 
  • Enlivex expects that broad acceptance of the proposed amendments will shorten the timeline for potential regulatory approval of frozen Allocetra formulation in sepsis and its associated commercial launch.
  • In addition, the frozen formulation of Allocetra is expected to have a shelf-life spanning multiple years, versus a shelf life of 96 hours for the previously used liquid formulation.
  • We are better positioned to build on our positive Phase Ib results and accelerate the advancement of our sepsis program, said Oren Hershkovitz, Ph.D., CEO of Enlivex.
  • Enlivexs Phase II sepsis trial is a placebo-controlled, randomized, dose-finding, multi-center study that is currently enrolling patients across four cohorts.

Innoviva Completes Acquisition of La Jolla Pharmaceutical

Retrieved on: 
Monday, August 22, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Security (finance), Philippe Ciais, II, Securities Exchange Act of 1934, Tax, Nasdaq, Multiplicity of infection, Exercise, Fluticasone furoate/umeclidinium bromide/vilanterol, Angiotensin, GSK, Coronavirus, Result, Distributive shock, Physician, Septic, Infection, Data analysis, U.S. Securities and Exchange Commission, Hospital, Goal, Blood pressure, Communication, Financial condition report, Analysis, Private Securities Litigation Reform Act, Acquisition, Patient, Pharmaceutical industry, Risk management, Entasis

Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.

Key Points: 
  • Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.
  • The acquisition of La Jolla strengthens our footprint in the hospital and infectious disease spaces by adding a robust portfolio of marketed products and an excellent team, said Pavel Raifeld, Chief Executive Officer of Innoviva.
  • All conditions of the offer were satisfied and Innoviva completed its acquisition of all issued and outstanding equity securities of La Jolla for the Offer Price.
  • As a result of the acquisition, La Jolla became a wholly-owned subsidiary of Innoviva and the companys common stock will be delisted from the Nasdaq Global Market.

Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan

Retrieved on: 
Thursday, August 11, 2022
Social conditions in Honduras, Gastrointestinal tract, Cholecystitis, Aerobic organism, NDA, Peritonitis, MDR, Daptomycin, Technology, Multiplicity of infection, Philippe Ciais, Cancer, Life, Critical care, Marketing, Patient, Review, Bronchopneumonia, Stomach, Appendicitis, Company, Infection, HKEX, Partnership, Tetracycline, Doctor of Philosophy, Degenerative disease, Perforation, News, TTY, Gram-positive bacteria, Solution, CMC, Diverticulitis, Medicine, Food, Terminology, Pharmaceutical industry, Vaccine, Colistin, Eravacycline, Mount Everest, MD

SHANGHAI, Aug. 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that the Taiwan Food and Drug Administration (TFDA) has accepted the submission of a New Drug Application (NDA) for Xerava™ (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI).

Key Points: 
  • In addition, the Company has entered into an exclusive partnership agreement with TTY Biopharm (TTY) for commercialization of Xerava in Taiwan.
  • It is not only being one of the top pharmaceutical companies in Taiwan, but also focuses on international marketing.
  • Under the partnership, which includes a 10-year term upon the launch of Xerava in Taiwan with possibility of extension, TTY will be responsible for all commercialization of the product in Taiwan.
  • Everest Medicines has built a portfolio of elevenpotentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development.

DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY

Retrieved on: 
Monday, August 1, 2022
IDSA, Philippe Ciais, Anesthesia, Infection, EU, Infectious Diseases Society of America, Ertapenem, Abscess, Distributive shock, ISIN, Remimazolam, Intra-abdominal infection, Angiotensin, Tetracycline, PA8, Royal commission, Eravacycline, Sepsis, Federal Joint Committee (Germany), Septic, Hypotension, Aachen, Product, Abdominal cavity, European Commission, European Medicines Agency, Frankfurt Stock Exchange, Patient, Health, Peritonitis, Multiplicity of infection, Meropenem, ICU, Critical care, Dietary supplement, Pharmaceutical industry, European

In April 2022, the Federal Joint Committee (G-BA) voted in favour of PAIONs application for eravacycline as a reserve antibiotic.

Key Points: 
  • In April 2022, the Federal Joint Committee (G-BA) voted in favour of PAIONs application for eravacycline as a reserve antibiotic.
  • Eravacycline is approved by the European Commission and the UK Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI) in adults.
  • Eravacycline is an important new treatment option for patients suffering from serious intra-abdominal infections.
  • Eravacycline is an antibiotic used to treat complicated intra-abdominal infections (cIAI) in adults.

Innoviva to Acquire La Jolla Pharmaceutical Company

Retrieved on: 
Monday, July 11, 2022
Health, Pharmaceutical, COMMON, FDA, Multiplicity of infection, Septic, Attention, LLP, LLC, Schedule TO, II, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., TRC, Blood pressure, Philippe Ciais, Fluticasone furoate/umeclidinium bromide/vilanterol, U.S. Securities and Exchange Commission, Tetracycline, LA, Distributive shock, Infection, Patient, SEC, Growth, Strategic alliance, Tower of Power (transmitter), EACH, Schedule, Food, Company, Patent, Nasdaq, Report, Security (finance), Angiotensin, Industry, Criticism of the Food and Drug Administration, Gibson, Dunn & Crutcher, Risk, TIME, Acquisition, Letter of transmittal, GlaxoSmithKline, GSK, VWAP, Letter, Willkie Farr & Gallagher, Pharmaceutical industry, Risk management, Cryptocurrency

(Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.

Key Points: 
  • (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.
  • We look forward to welcoming the La Jolla team to Innoviva and building upon the success of GIAPREZA and XERAVA.
  • We are pleased to announce the acquisition of La Jolla by Innoviva, which we believe provides our stockholders with immediate value at a compelling premium, said Larry Edwards, President and Chief Executive Officer of La Jolla.
  • La Jolla Pharmaceutical Company is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.

Innoviva to Acquire La Jolla Pharmaceutical Company

Retrieved on: 
Monday, July 11, 2022
Health, Infectious Diseases, General Health, Pharmaceutical, Cardiology, Biotechnology, COMMON, FDA, Multiplicity of infection, Septic, Attention, LLP, LLC, Schedule TO, Multimedia, II, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., TRC, Blood pressure, Philippe Ciais, Fluticasone furoate/umeclidinium bromide/vilanterol, U.S. Securities and Exchange Commission, Tetracycline, LA, Distributive shock, Infection, Patient, SEC, Growth, Strategic alliance, Tower of Power (transmitter), EACH, Schedule, Food, Company, Patent, Nasdaq, Report, Security (finance), Angiotensin, Industry, Criticism of the Food and Drug Administration, Gibson, Dunn & Crutcher, Risk, TIME, Acquisition, Letter of transmittal, GlaxoSmithKline, GSK, VWAP, Letter, Willkie Farr & Gallagher, Pharmaceutical industry, Risk management, Cryptocurrency

Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.

Key Points: 
  • Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.
  • We look forward to welcoming the La Jolla team to Innoviva and building upon the success of GIAPREZA and XERAVA.
  • We are pleased to announce the acquisition of La Jolla by Innoviva, which we believe provides our stockholders with immediate value at a compelling premium, said Larry Edwards, President and Chief Executive Officer of La Jolla.
  • La Jolla Pharmaceutical Company is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.

DGAP-News: ​​​​​​​PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD

Retrieved on: 
Wednesday, May 25, 2022
MBA, Health, General manager, Supervisory board, Septic, Angiotensin, ISIN, Annual, Patient, EU, Hypotension, Financial Oversight and Management Board for Puerto Rico, University of Bonn, Marketing, Anesthesia, Critical care, Frankfurt Stock Exchange, Distributive shock, Biotechnology, Cene Prevc, Diple, University, Multiplicity of infection, Country, Remimazolam, Annual general meeting, Abbott, AGR, CEO, Pharmaceutical industry, Pfizer

In addition, Michael Schlenk and Gregor Siebert were elected to the Supervisory Board, replacing Dr Dr Irina Antonijevic and Dr Jrg Spiekerktter.

Key Points: 
  • In addition, Michael Schlenk and Gregor Siebert were elected to the Supervisory Board, replacing Dr Dr Irina Antonijevic and Dr Jrg Spiekerktter.
  • Mr Schlenk will take over the chairmanship of the Supervisory Board from Dr Spiekerktter.
  • "We are delighted to have gained two recognised experts from the pharmaceutical industry as members of PAION AG's Supervisory Board.
  • Michael Schlenk, designated Chairman of the Supervisory Board of PAION AG, commented: "I am delighted about the election to the Supervisory Board by the Annual General Meeting.

Global Carbapenem-Based Antibiotics Market Forecast Report to 2028: Rising Prevalence of Gram-Negative Bacterial Infections and Increasing Production of Generic Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 10, 2022
Infectious Diseases, Pharmaceutical, Health, COVID-19, Population, Distribution, Urinary tract infection, Imipenem, Geography, Market share, Meningitis, Adoption, Vaccine, Infection, Pharmacy, CAGR, Multiplicity of infection, Research, Growth, Pharmaceutical industry, Dietary supplement, Agriculture, Doripenem, Meropenem

The "Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Indication, and Distribution Channel" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Indication, and Distribution Channel" report has been added to ResearchAndMarkets.com's offering.
  • In addition, the expiry of patented carbapenem-based antibiotics has widen-up opportunities for generic drug manufacturers to enter the market with their cost-efficient drugs.
  • The others segment held the largest market share of the carbapenem based antibiotics market in 2021, and it is anticipated to register the highest CAGR in the carbapenem-based antibiotics market during the forecast period.
  • Based on indication, the carbapenem-based antibiotics market is segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others.

DGAP-News: PAION AG ANNOUNCES CHANGE IN MANAGEMENT BOARD

Retrieved on: 
Friday, April 1, 2022
Company, University, Septic, Anesthesia, Aachen, Health, Distributive shock, CFO, Supervisory board, Multiplicity of infection, Financial Oversight and Management Board for Puerto Rico, Hoffmann-La Roche, CEO, Angiotensin, EU, ISIN, Critical care, MBA, Frankfurt Stock Exchange, Hypotension, Erlangen, Patient, Remimazolam, Management, Pharmaceutical industry, Central Europe

Aachen (Germany), 30 March 2022 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that Sebastian Werner has been appointed by the Supervisory Board as a new member of the Management Board in the position as Chief Financial Officer ("CFO") of PAION AG with effect from 1 June 2022.

Key Points: 
  • Aachen (Germany), 30 March 2022 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that Sebastian Werner has been appointed by the Supervisory Board as a new member of the Management Board in the position as Chief Financial Officer ("CFO") of PAION AG with effect from 1 June 2022.
  • "With his many years of international expertise in the pharmaceutical industry, Sebastian Werner is an excellent addition to the Management Board of PAION AG.
  • I wish him every success in his new role," said Dr. Jrg Spiekerktter, Chairman of the Supervisory Board of PAION AG.
  • "My special and sincere thanks also go to Mr. Omari for his successful work and great commitment to PAION over the past 14 years," commented Dr. Jrg Spiekerktter, Chairman of the Supervisory Board of PAION AG.

Investigation Report on China's Tigecycline Markets, 2016-2020 & 2021-2025: A Broad-spectrum Glycyl Cyclic Peptide Antibiotic Administered Intravenously - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Health, Pharmaceutical, Ageing, Multiplicity of infection, Methicillin-resistant Staphylococcus aureus, World Health Organization, Infection, MRSA, World, Hospital-acquired pneumonia, Death, Skin, Patient, COVID-19, CAGR, Review, Animal, Pharmaceutical industry, Iron, Fine chemical, Motor vehicle, Tigecycline

The "Investigation Report on China's Tigecycline Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Tigecycline Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Tigecycline is a broad-spectrum glycyl cyclic peptide antibiotic administered intravenously.
  • Tigecycline is approved for complicated skin and skin structure infections or complicated intra-abdominal infections patients aged 18 and over.
  • By 2020, tigecycline has been included in China's Class B medical insurance, and there are several manufacturers in the Chinese tigecycline market.